Low mortality, stroke seen with newest Edwards TAVR system -study

March 15 (Reuters) - Researchers on Sunday presented trial data showing very low mortality and stroke rates using the third generation version of Edwards Lifesciences Corp's non-invasive heart valve replacement system that could help support its U.S. approval.